Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

NCT02338050 is registered in ClinicalTrials.gov with Center for International Blood and Marrow Transplant Research as lead sponsor.

NCT NCT02338050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02338050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Center for International Blood and Marrow Transplant Research
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2015
Completion date
Not reported
Enrollment
1 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia (all)